Clinical trial
Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in…
NCT00333411 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00333411 |
|---|---|
| Title | Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis |
| Official title | A 12 Week Double-blind, Randomised, Placebo-controlled, Modified Dose-escalation Trial to Investigate Safety, Efficacy, and Pharmacokinetics of BIRT 2584XX Tablets at Doses of 100, 300 and 500 mg Administered Once Daily in Patients With Moderate to Severe Psoriasis With a 12 Week Treatment Extension |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | BIRT 2584 XX, Placebo |
| Enrollment | 360 |
| Start date | Jun 1, 2006 |
| Primary completion | Jun 1, 2008 |
| First posted | Jun 5, 2006 |
| Last update posted | Jun 19, 2014 |
| Countries | Belgium, Canada, Denmark, Finland, France, Germany, Netherlands, Spain, Sweden, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: